David R. Goldsmith, MD

  • 2Articles
  • 7.9KReads
  • 2017–2018Active
  • 2Collaborators
  • 83Citations

About

David R. Goldsmith, MD, has published research on mood disorders and schizophrenia/schizoaffective disorders. His work includes studies on lithium augmentation in clozapine rechallenge following neutropenia or agranulocytosis, as well as the development of screening protocols for clozapine-induced myocarditis. His publications appeared between 2017 and 2018 in Psychiatrist.com (The Journal of Clinical Psychiatry and The Primary Care Companion for CNS Disorders). He has frequently collaborated with Robert O. Cotes and Mina Boazak.

Publications

PCC
Letter to the Editor

Lithium Augmentation for Clozapine Rechallenge: Discontinuation Might Be Risky

November 29, 2018

Is lithium needed long term after clozapine rechallenge? Do individuals develop neutropenia or agranulocytosis after lithium is discontinued? The authors of this report analyzed all of the available literature...
, ,
PCC
Letter to the Editor

Clozapine-Induced Myocarditis Screening Protocol

August 3, 2017

Clinicians should be able to recognize and manage potential side effects of clozapine, including myocarditis. However, treatment guidelines do not currently recommend a monitoring protocol for clozapine-induced myocarditis. This...
,

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe